CORRECTED-UPDATE 4-Biosimilar worries takes shine off Roche's guidance hike

ZURICH, April 26 (Reuters) - Cheaper copies of Roche's Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines.